JP6999648B2 - インスリン投薬計画における基礎／ボーラス比を調節するためのシステムおよび方法 - Google Patents
インスリン投薬計画における基礎／ボーラス比を調節するためのシステムおよび方法 Download PDFInfo
- Publication number
- JP6999648B2 JP6999648B2 JP2019508874A JP2019508874A JP6999648B2 JP 6999648 B2 JP6999648 B2 JP 6999648B2 JP 2019508874 A JP2019508874 A JP 2019508874A JP 2019508874 A JP2019508874 A JP 2019508874A JP 6999648 B2 JP6999648 B2 JP 6999648B2
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- bolus
- subject
- basal
- daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 1069
- 102000004877 Insulin Human genes 0.000 title claims description 535
- 108090001061 Insulin Proteins 0.000 title claims description 535
- 229940125396 insulin Drugs 0.000 title claims description 534
- 238000000034 method Methods 0.000 title claims description 78
- 230000001105 regulatory effect Effects 0.000 title description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 264
- 239000008103 glucose Substances 0.000 claims description 264
- 229940079593 drug Drugs 0.000 claims description 255
- 239000003814 drug Substances 0.000 claims description 255
- 238000005259 measurement Methods 0.000 claims description 184
- 238000002347 injection Methods 0.000 claims description 148
- 239000007924 injection Substances 0.000 claims description 148
- 239000003795 chemical substances by application Substances 0.000 claims description 47
- 230000000291 postprandial effect Effects 0.000 claims description 41
- 230000015654 memory Effects 0.000 claims description 40
- 229940127560 insulin pen Drugs 0.000 claims description 39
- 230000002123 temporal effect Effects 0.000 claims description 32
- 235000021152 breakfast Nutrition 0.000 claims description 24
- 230000007812 deficiency Effects 0.000 claims description 18
- 230000009471 action Effects 0.000 claims description 17
- 238000002483 medication Methods 0.000 claims description 13
- 238000004590 computer program Methods 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000013500 data storage Methods 0.000 claims description 3
- 238000004891 communication Methods 0.000 description 20
- 235000005911 diet Nutrition 0.000 description 15
- 230000000378 dietary effect Effects 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 238000007726 management method Methods 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000003914 insulin secretion Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 238000013439 planning Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000012937 correction Methods 0.000 description 5
- 238000013480 data collection Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000012806 monitoring device Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 108010065920 Insulin Lispro Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 3
- 108010092217 Long-Acting Insulin Proteins 0.000 description 3
- 102000016261 Long-Acting Insulin Human genes 0.000 description 3
- 229940100066 Long-acting insulin Drugs 0.000 description 3
- 108010026951 Short-Acting Insulin Proteins 0.000 description 3
- 229940123958 Short-acting insulin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229960002068 insulin lispro Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108010057186 Insulin Glargine Proteins 0.000 description 2
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 229960004717 insulin aspart Drugs 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 240000007839 Kleinhovia hospita Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010050259 insulin degludec Proteins 0.000 description 1
- 229960004225 insulin degludec Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940112879 novolog Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000004171 remote diagnosis Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940026454 tresiba Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Databases & Information Systems (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Business, Economics & Management (AREA)
- Business, Economics & Management (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16184451.9 | 2016-08-17 | ||
| EP16184451 | 2016-08-17 | ||
| PCT/EP2017/070585 WO2018033514A1 (en) | 2016-08-17 | 2017-08-14 | Systems and methods for adjusting a basal/bolus ratio in an insulin regimen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532391A JP2019532391A (ja) | 2019-11-07 |
| JP2019532391A5 JP2019532391A5 (enExample) | 2021-10-07 |
| JP6999648B2 true JP6999648B2 (ja) | 2022-01-18 |
Family
ID=56740110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508874A Active JP6999648B2 (ja) | 2016-08-17 | 2017-08-14 | インスリン投薬計画における基礎／ボーラス比を調節するためのシステムおよび方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11462313B2 (enExample) |
| EP (1) | EP3500962B1 (enExample) |
| JP (1) | JP6999648B2 (enExample) |
| CN (1) | CN109564776B (enExample) |
| MA (1) | MA45980A (enExample) |
| WO (1) | WO2018033514A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111833985B (zh) * | 2019-04-17 | 2023-04-07 | 复旦大学附属中山医院 | 胰岛素剂型选择及剂量调整方法及系统 |
| JP7599439B2 (ja) * | 2019-06-05 | 2024-12-13 | サノフイ | 基礎インスリン用量およびボーラスインスリン用量を投与する医療デバイスおよび方法 |
| BR112022005648A2 (pt) * | 2019-09-25 | 2022-07-19 | Janssen Pharmaceuticals Inc | Sistema de administração de fármacos configurado para determinar um esquema de dosagem de fármacos |
| CN115804593A (zh) * | 2021-09-15 | 2023-03-17 | 深圳硅基仿生科技股份有限公司 | 针对用餐前后的葡萄糖浓度水平的葡萄糖监测系统 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090036753A1 (en) | 2007-07-31 | 2009-02-05 | King Allen B | Continuous glucose monitoring-directed adjustments in basal insulin rate and insulin bolus dosing formulas |
| JP2009037588A (ja) | 2007-03-20 | 2009-02-19 | Lifescan Inc | 糖尿病の管理用プログラム |
| US20110319322A1 (en) | 2008-04-04 | 2011-12-29 | Hygieia, Inc. | Systems, Methods and Devices for Achieving Glycemic Balance |
| JP2013501989A (ja) | 2009-08-10 | 2013-01-17 | ディアベテス トールス スウェーデン アーべー | 血糖データを処理する装置および方法 |
| JP2013529500A (ja) | 2010-06-22 | 2013-07-22 | メドトロニック ミニメド インコーポレイテッド | 患者の体内の血中グルコース濃度レベルを制御するための装置 |
| US20150217055A1 (en) | 2014-01-31 | 2015-08-06 | Aseko, Inc. | Insulin Management |
| JP2015528348A (ja) | 2012-08-30 | 2015-09-28 | メドトロニック ミニメド インコーポレイテッド | インスリン注入デバイスを制御するシステム及び方法 |
| US20150366945A1 (en) | 2014-06-20 | 2015-12-24 | Howard E. Greene | Infusion delivery devices and methods |
| WO2016069475A1 (en) | 2014-10-27 | 2016-05-06 | Aseko, Inc. | Subcutaneous outpatient management |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007051139A2 (en) | 2005-10-27 | 2007-05-03 | Insulet Corporation | Diabetes management systems and methods |
| US10010669B2 (en) | 2006-02-09 | 2018-07-03 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
| US8380530B2 (en) * | 2007-02-02 | 2013-02-19 | Webmd Llc. | Personalized health records with associative relationships |
| US10624577B2 (en) * | 2008-04-04 | 2020-04-21 | Hygieia, Inc. | Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus |
| WO2009139846A1 (en) | 2008-05-12 | 2009-11-19 | Department Of Veterans Affairs | Automated system and method for diabetes control |
| WO2010056718A2 (en) * | 2008-11-11 | 2010-05-20 | Hygieia, Inc. | Apparatus and system for diabetes management |
| US9724475B2 (en) * | 2009-02-27 | 2017-08-08 | Lifescan, Inc. | Drug delivery management systems and methods |
| CN102667787A (zh) * | 2009-09-30 | 2012-09-12 | 莫尔研究应用有限公司 | 管理胰岛素输注的监视装置 |
| WO2011089600A1 (en) * | 2010-01-20 | 2011-07-28 | Medingo Ltd. | A method and device for improving glycemic control |
| WO2012122520A1 (en) * | 2011-03-10 | 2012-09-13 | Abbott Diabetes Care Inc. | Multi-function analyte monitor device and methods of use |
| CN104053396B (zh) * | 2011-12-15 | 2016-12-21 | 贝克顿·迪金森公司 | 用于改进的生理数据的解释和生理状况管理信息的呈现的系统 |
| US9990581B2 (en) * | 2012-07-11 | 2018-06-05 | Roche Diabetes Care, Inc. | Insulin dosage assessment and recommendation system |
| GB201407896D0 (en) | 2014-05-05 | 2014-06-18 | Joanneum Res Forschungsgmbh | Insulin dosage proposal system |
| HUE053370T2 (hu) * | 2014-09-22 | 2021-06-28 | Dexcom Inc | Eljárás üzemmód átkapcsolásra |
| US20160082187A1 (en) * | 2014-09-23 | 2016-03-24 | Animas Corporation | Decisions support for patients with diabetes |
| WO2016182200A1 (en) * | 2015-05-12 | 2016-11-17 | Samsung Electronics Co., Ltd. | Blood glucose measurement apparatus and blood glucose measurement method thereof |
-
2017
- 2017-08-14 JP JP2019508874A patent/JP6999648B2/ja active Active
- 2017-08-14 US US16/323,600 patent/US11462313B2/en active Active
- 2017-08-14 WO PCT/EP2017/070585 patent/WO2018033514A1/en not_active Ceased
- 2017-08-14 EP EP17755131.4A patent/EP3500962B1/en active Active
- 2017-08-14 MA MA045980A patent/MA45980A/fr unknown
- 2017-08-14 CN CN201780050301.7A patent/CN109564776B/zh active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009037588A (ja) | 2007-03-20 | 2009-02-19 | Lifescan Inc | 糖尿病の管理用プログラム |
| US20090036753A1 (en) | 2007-07-31 | 2009-02-05 | King Allen B | Continuous glucose monitoring-directed adjustments in basal insulin rate and insulin bolus dosing formulas |
| US20110319322A1 (en) | 2008-04-04 | 2011-12-29 | Hygieia, Inc. | Systems, Methods and Devices for Achieving Glycemic Balance |
| JP2013501989A (ja) | 2009-08-10 | 2013-01-17 | ディアベテス トールス スウェーデン アーべー | 血糖データを処理する装置および方法 |
| JP2013529500A (ja) | 2010-06-22 | 2013-07-22 | メドトロニック ミニメド インコーポレイテッド | 患者の体内の血中グルコース濃度レベルを制御するための装置 |
| JP2015528348A (ja) | 2012-08-30 | 2015-09-28 | メドトロニック ミニメド インコーポレイテッド | インスリン注入デバイスを制御するシステム及び方法 |
| US20150217055A1 (en) | 2014-01-31 | 2015-08-06 | Aseko, Inc. | Insulin Management |
| US20150366945A1 (en) | 2014-06-20 | 2015-12-24 | Howard E. Greene | Infusion delivery devices and methods |
| WO2016069475A1 (en) | 2014-10-27 | 2016-05-06 | Aseko, Inc. | Subcutaneous outpatient management |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109564776A (zh) | 2019-04-02 |
| US20190164641A1 (en) | 2019-05-30 |
| EP3500962B1 (en) | 2024-10-09 |
| JP2019532391A (ja) | 2019-11-07 |
| MA45980A (fr) | 2019-06-26 |
| US11462313B2 (en) | 2022-10-04 |
| WO2018033514A1 (en) | 2018-02-22 |
| CN109564776B (zh) | 2023-09-26 |
| EP3500962A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3549133B1 (en) | Starter kit for basal rate titration | |
| US20190180856A1 (en) | Systems and methods for optimization of a bolus insulin medicament dosage for a meal event | |
| JP6756030B2 (ja) | 適応的目標グルコース値による基礎滴定 | |
| CN109661706B (zh) | 用于确定胰岛素敏感性的系统和方法 | |
| US11282598B2 (en) | Starter kit for basal insulin titration | |
| JP7018937B2 (ja) | 基礎投与のタイミングを調節するためのシステムおよび方法 | |
| JP6999648B2 (ja) | インスリン投薬計画における基礎／ボーラス比を調節するためのシステムおよび方法 | |
| US11631486B2 (en) | Systems and methods for optimization of bolus timing relative to meal events | |
| JP6940531B2 (ja) | インスリン計画アドヒアランスデータの分析のためのシステムおよび方法 | |
| JP6780035B2 (ja) | グルコース測定値およびインスリンペンデータに基づくインスリン治療のための計画アドヒアランス測定 | |
| JP7064452B2 (ja) | インスリン計画アドヒアランスデータの分析のためのシステムおよび方法 | |
| WO2018099912A1 (en) | Starter kit for basal rate titration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200713 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210330 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20210629 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211222 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6999648 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |